Tolerability and Efficacy of UV1 Vaccine in Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma Planned for First-line Treatment With Pembrolizumab
Clinical trial NCT05075122 · UNKNOWN
Trial details
- NCT number
- NCT05075122
- Sponsor
- Martin-Luther-Universität Halle-Wittenberg
- Status
- UNKNOWN
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2021-08-02
- Primary completion
- 2024-08-01
- Enrollment
- 75
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.